Company Name: ZS Pharma Inc.
Location: Ft. Worth, Texas
Solution/Product: ZS-9, an oral sorbent technology platform that will first be applied to removing toxins in patients suffering from hyperkalemia, or high levels of potassium in the blood, as a result of kidney and liver disease and related conditions.
Money Raised: $5.3 million since November
How will it be used: First round of clinical trials to test the drug in acute hyperkalemia, according to the Dallas Business Journal. President and CEO Al Guillem wasn’t immediately available to comment.
Investors: The filing lists Marc Ostro, of Devon Park Bioventures, and Robert Truitt, of Ash Access Technology, among the company’s board of directors. In 2010, ZS Pharma received $2 million from the state’s Emerging Technology Fund.
Reserve your seat now for MedCity CONVERGE, to be held July 9-10 in Philadelphia. Discover strategies, solutions and startups in healthcare innovation. Be a part of this gathering where the entire healthcare ecosystem converges.